Table 2_Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis.xlsx

Table 2_Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis.xlsx

Background<p>Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that is effective in treating gastrointestinal (GI) cancers. However, the significant variability in its reported efficacy and safety profiles is likely due to differences in trial designs, patient populations, and...

Full description

Saved in:
Bibliographic Details
Main Author: Ali Hussain (623555) (author)
Other Authors: Qamar Iqbal (13914999) (author), Sangeetha Isaac (21195887) (author), Faisal Shariff (21195890) (author), Ezza Tariq (13914996) (author), Hassan Awais (21195893) (author), Nayan Mainkar (21195896) (author), Heidi Lynn Reis (21195899) (author), Aakriti Arora (15514385) (author), Akshay Deotare (21195902) (author), Azka Tasleem (21195905) (author), Srijan Valasapalli (21195908) (author), Munizay Paracha (21195911) (author), Maya Hashmi (21195914) (author), Hamdi Battah (21195917) (author), Mahvish Muzaffar (195405) (author)
Published: 2025
Subjects:
Gastroenterology and Hepatology
trastuzumab deruxtecan (T-DXd)
antibody-drug conjugate (ADC)
gastrointestinal malignancies
safety
efficacy
HER2-positive
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items